Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence (NCT06721351)
Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence -DRES-POCAI: AI - Clinical Intervention at San Ysidro Health
🩺 Plain-English Summary (8th-Grade Level)
This research study is being conducted to improve eye care by using artificial intelligence (AI) to make diabetic eye screenings faster and more accessible. AI technology mimics human decision-making, enabling computers and systems to analyze medication information. Specifically for this screening, AI examines digital images of the eye and based on that information, may identify if a participant has diabetic retinopathy. It can assist doctors in making decisions about a participant's diagnosis, treatment or care plans to improve patient care. This is a collaboration between San Ysidro Health (SYHealth), University of California, San Diego (UC San Diego), and Eyenuk. The Kaiser Permanente Augmented Intelligence in Medicine and Healthcare Initiative (AIM-HI) awarded SYHealth funds to demonstrate the value of AI technologies in diverse, real-world settings.
Who can join: Review the eligibility criteria below.
Location: San Ysidro Health Chula Vista — Chula Vista, California
Age range: 22 Years
🧪 Interventions in This Study
- Diabetic Retinopathy screening Point of Care Artificial Intelligence (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- San Ysidro Health Chula Vista — Chula Vista, California
- San Ysidro Health - Comprehensive Health Center - Ocean View — San Diego, California
- San Ysidro Health King-Chavez Health Center — San Diego, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetic Retinopathy (DR)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) — Phoenix, Arizona
- Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center — San Francisco, California
- Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE) — Chicago, Illinois
- Assessment of AI Program 'DRISTi' as a Screening Tool — Oxford, North Carolina
Explore by condition: All Diabetic Retinopathy (DR) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.